Pain medication use and risk of renal cell carcinoma

Findings from the CONFIRM Project

Renal cell carcinoma (RCC) is the most common type of kidney cancer, and its incidence is rising. Laboratory studies have shown that pain medication such as paracetamol, aspirin and other nonsteroidal anti- inflammatory drugs affect kidney function. Several studies have investigated their association with risk of RCC, and while some have found an association, others have not. Given the widespread use of these medicines, it is important to clarify whether they are associated with risk of RCC.

This large study, led by Dr Fiona Bruinsma, recruited people with RCC from population-based cancer registries. It also recruited their siblings and spouses as controls. The researchers are comparing pain medication use between those with and without RCC and, taking into account other key differences between the two groups.

These findings could help inform clinical advice to reduce the risk of renal cell carcinoma. This study could also guide future, more detailed research examining how specific types of pain medication are associated with RCC risk.

This work is being prepared for publication.